Clinical Application Of Cordyceps Sinensis On Immunosuppressive Therapy In Renal Transplantation
| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 167 |
| Gender | Both Genders |
| Age Range | 30-44 |
In patients who were going to undergo renal transplants, divided into either a control group given standard immunosuppressive therapy (pulse therapy with methylprednisolone, and cyclophosphamide followed later by mycophenolate mofetil and prednisone) or an experimental group given the aforementioned but with cordyceps (c. sinensis) at 1g three times daily, supplementation was found to confer more benefits than control without cordyceps.
There were reductions in instances of organ damage (liver and kidney; from 18.35% down to 7.53%), serum uric acid, urinary proteins (from 2.25+/-0.58g down to 1.77+/-0.43g), total bilirubin, and serum creatinine; ALT (biomarker for liver damage) among patients without hepatotoxicity did not differ.
Overall survival rates did not differ between groups.
